A hirsutism hormone panel measures androgens that can drive coarse, dark hair growth in areas such as the face, chest, abdomen, back, or thighs. Total and free testosterone are the most informative first tests for biochemical androgen excess. DHEA-S mainly reflects adrenal androgen production, while androstenedione comes from both the ovaries and adrenal glands. Polycystic ovary syndrome is the most common cause of gradually developing hirsutism, but normal androgen results are also possible because hair follicles differ in sensitivity. Testing is especially important when hair growth is moderate or severe, progresses quickly, occurs with irregular periods or infertility, or is accompanied by acne, scalp hair loss, or virilization. Results depend on assay quality, age, hormonal contraception, sex hormone-binding globulin, and menstrual timing. The panel does not diagnose PCOS or locate a tumor by itself. A reliable diagnosis combines the hair pattern, rate of change, menstrual and medication history, physical examination, additional blood tests, and imaging only when the hormone pattern justifies it.
- Testosterone is the primary androgen test: free testosterone can uncover excess when SHBG is low.
- DHEA-S points mainly to the adrenal glands: marked elevation requires focused adrenal evaluation.
- Androstenedione can add sensitivity: it is useful when testosterone is normal but suspicion remains.
- Gradual hirsutism with irregular periods commonly reflects PCOS: rapid virilization is not typical and needs prompt assessment.
- Normal hormones do not rule out clinically important hirsutism: follicle sensitivity and idiopathic hirsutism can produce normal blood results.
Table of Contents
- What Hirsutism Means and When Testing Helps
- What Testosterone, DHEA-S, and Androstenedione Measure
- Test Preparation and Reliable Measurement
- Interpreting Hormone Result Patterns
- Common and Important Causes of Hirsutism
- Additional Tests and When Imaging Is Needed
- Treatment, Hair Removal, and Red Flags
What Hirsutism Means and When Testing Helps
Hirsutism is excessive terminal hair growth in an androgen-dependent pattern. Terminal hairs are coarse, pigmented, and longer than the fine vellus hairs that cover much of the body. Typical androgen-sensitive sites include the upper lip, chin, sideburn area, chest, upper and lower abdomen, back, upper arms, and thighs.
Hirsutism is different from hypertrichosis, which is increased hair growth in a nonandrogen pattern. Hypertrichosis may be genetic or related to medicines such as minoxidil, cyclosporine, or phenytoin. It does not necessarily indicate high testosterone.
Clinicians may grade hirsutism with a modified Ferriman-Gallwey score, which rates terminal hair in several body areas. The cutoff that represents abnormal growth varies with ethnicity, age, hair-removal practices, and the scoring system. A person can have distressing facial hair despite a score below a traditional research cutoff, while frequent removal can hide the original severity.
Who benefits most from blood testing
Androgen testing is useful for women with an abnormal hirsutism score, moderate or severe hair growth, menstrual disturbance, infertility, rapid progression, or other signs of endocrine disease. It is also appropriate when mild hair growth continues to worsen despite treatment.
Testing has a low yield for a few unwanted local hairs in a woman with regular cycles and no other signs of androgen excess. In that situation, cosmetic treatment may be reasonable without an extensive endocrine panel, although patient concern and clinical judgment still matter.
Important accompanying features include:
- periods more than about 35 days apart, fewer than eight cycles per year, or amenorrhea;
- persistent acne or oily skin;
- widening of the scalp part or temporal recession;
- difficulty conceiving;
- acanthosis nigricans or other signs of insulin resistance;
- weight change or Cushing-like features;
- a deepening voice, clitoral enlargement, rapid muscle gain, or breast tissue reduction.
The last group represents virilization and deserves faster evaluation. Hirsutism usually develops over years in PCOS. A change over several months, especially after menopause, is more concerning for ovarian hyperthecosis, a tumor, or exogenous androgen exposure.
Hair growth can have a major emotional effect regardless of the laboratory result. Clinicians should ask how much time, expense, skin irritation, or distress hair removal causes rather than judging severity only by an examination score.
What Testosterone, DHEA-S, and Androstenedione Measure
The panel examines androgens from overlapping sources. No single hormone perfectly distinguishes ovarian from adrenal production, but the pattern narrows the possibilities.
Total and free testosterone
Testosterone is the main circulating androgen used to assess hyperandrogenism. The ovaries and adrenal glands contribute directly, and peripheral tissues convert androstenedione into testosterone.
Total testosterone includes hormone bound to sex hormone-binding globulin, loosely bound to albumin, and unbound. Free testosterone is the small unbound fraction. When SHBG is low because of insulin resistance, obesity, hypothyroidism, or androgen exposure, free testosterone can be high even while total testosterone remains within range.
A free testosterone assessment is most reliable when calculated from high-quality total testosterone, SHBG, and albumin or measured by equilibrium dialysis. Many direct free-testosterone immunoassays perform poorly at female concentrations.
DHEA-S
Dehydroepiandrosterone sulfate is produced almost entirely by the adrenal cortex. Its long half-life makes it relatively stable during the day and menstrual cycle. Mild elevation can occur in PCOS, while a marked age-adjusted increase raises concern for an adrenal source such as a tumor or, less often, another adrenal disorder.
DHEA-S normally peaks in early adulthood and declines with age. A result must be compared with an age-specific reference range. Taking over-the-counter DHEA can raise it and worsen facial hair, acne, or scalp thinning.
Androstenedione
Androstenedione, often written A4, is produced by both the ovaries and adrenal glands. It is a precursor to testosterone and estrone. Some women with PCOS or nonclassic congenital adrenal hyperplasia have elevated A4 even when testosterone is not clearly high.
Current guidance generally starts with total and free testosterone. DHEA-S and androstenedione can be added when those results are normal but clinical suspicion remains, or when the clinician needs a broader biochemical profile. A4 is less specific than testosterone for PCOS and should not be used alone to make the diagnosis.
The panel measures circulating hormones, not the amount of dihydrotestosterone inside a hair follicle or the sensitivity of the androgen receptor. This explains why blood values and hair-growth severity correlate only weakly.
Test Preparation and Reliable Measurement
Women have much lower testosterone concentrations than men, so laboratory method is central to accuracy. Total testosterone should preferably be measured by liquid chromatography–tandem mass spectrometry, or LC-MS/MS. If an immunoassay produces a result that does not fit the symptoms, confirmation by mass spectrometry is appropriate.
Timing of the blood draw
For a full androgen-excess evaluation, morning collection after an overnight fast is often recommended. When cycles are regular, early follicular-phase testing can reduce variation. If periods are absent or unpredictable, testing can occur on another day as long as the context is documented.
DHEA-S varies less than testosterone across the day, but collecting the entire panel together improves consistency. Acute illness, major sleep disruption, and some medications can affect the endocrine picture.
Hormonal contraception
Combined hormonal contraception suppresses ovarian androgen production and raises SHBG. Reliable biochemical assessment of untreated androgen excess is therefore difficult while using it. If testing is necessary and pregnancy prevention can be maintained another way, a clinician may arrange a washout of at least three months. Stopping birth control is not required for every patient and should never occur without a safe plan.
Progestin implants, injections, fertility medications, menopausal hormone therapy, and ovarian-suppression treatments also affect results. Record the exact product and last dose.
Medicines, supplements, and exposure
Report testosterone, DHEA, pregnenolone, anabolic steroids, danazol, valproate, glucocorticoids, and compounded hormone products. Testosterone gel used by a partner can transfer through skin contact. A blood sample contaminated by gel near the venipuncture site can produce a dramatic false elevation.
High-dose biotin interferes with some immunoassays. The laboratory can advise whether it should be held before testing. Do not discontinue prescribed medicines without instructions.
What a reliable report should show
A useful report includes the units, laboratory reference interval, assay method, and age or sex-specific comparison. Total testosterone may be listed in ng/dL or nmol/L, DHEA-S in mcg/dL or micromoles per liter, and androstenedione in ng/dL, ng/mL, or nmol/L. Values cannot be compared across units without conversion.
Borderline or unexpected elevations are often repeated. A confirmed result is more important than one abnormal value from a low-quality assay.
Interpreting Hormone Result Patterns
There is no universal numeric cutoff for the panel because methods and reference populations differ. Interpretation begins with the upper limit printed on the report and then considers how far the result exceeds it.
Common patterns
| Testosterone | DHEA-S | Androstenedione | Possible interpretation |
|---|---|---|---|
| Mildly high | Normal or mildly high | Normal or high | PCOS is common; correlate with cycles and other criteria |
| Normal total, high free | Normal or mildly high | Variable | Low SHBG may increase the active fraction |
| Markedly high testosterone | Normal or variable | Variable | Ovarian tumor, hyperthecosis, exogenous androgen, or severe PCOS; urgent evaluation may be needed |
| Normal testosterone | Markedly high DHEA-S | High or normal | Adrenal source deserves focused assessment |
| Normal testosterone and DHEA-S | High A4 | PCOS, nonclassic CAH, or assay variation; add 17-OHP and clinical context | |
| All within range | All within range | All within range | Idiopathic hirsutism or follicle sensitivity remains possible |
A mild elevation with gradual symptoms is far more likely to represent PCOS than a tumor. A tumor becomes more concerning when testosterone is several times the upper limit, DHEA-S is markedly above the age range, or virilization progresses rapidly. Thresholds such as total testosterone near or above 5 nmol/L or DHEA-S around 700 mcg/dL are sometimes used to trigger urgent investigation, but laboratories and guidelines differ. These values are signals for clinical review, not diagnostic lines.
Why SHBG changes the picture
Low SHBG increases free testosterone. A woman with insulin resistance may therefore have normal total testosterone but biochemical hyperandrogenism on calculated free testosterone. Estrogen-containing contraception can raise SHBG and make free testosterone look low while suppressing ovarian production.
Thyroid and liver disease also alter SHBG. Total testosterone, SHBG, and free testosterone should be reviewed together rather than treating the calculated value as independent.
Normal results
Normal androgens do not mean the hair growth is imagined or purely cosmetic. Idiopathic hirsutism is diagnosed when cycles and androgen tests are normal and other causes are excluded. Greater 5-alpha-reductase activity in skin, local dihydrotestosterone production, receptor sensitivity, and genetics may contribute.
Repeated broad hormone panels are rarely helpful when reliable results remain normal and symptoms are stable. Treatment can focus on the hair while clinicians remain alert for changes in cycles or progression.
Common and Important Causes of Hirsutism
Polycystic ovary syndrome
PCOS is the most common cause. It often produces gradual hirsutism beginning around puberty or early adulthood, irregular ovulation, acne, scalp thinning, infertility, and metabolic risk. Not every patient has ovarian “cysts,” and normal testosterone does not exclude PCOS when clinical hyperandrogenism and ovulatory dysfunction are present.
Diagnosis in adults generally requires two of three features—ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology or validated AMH criteria—after mimicking conditions are excluded. The LH-to-FSH ratio is not required and has no universal diagnostic cutoff.
Idiopathic hirsutism
Idiopathic hirsutism usually occurs with regular ovulatory cycles and normal measured androgens. It is a diagnosis of exclusion. It may run in families and can reflect increased follicle sensitivity. Treatment is guided by distress and hair-growth severity rather than the absence of a laboratory abnormality.
Nonclassic congenital adrenal hyperplasia
Nonclassic 21-hydroxylase deficiency can cause hirsutism, acne, irregular periods, and infertility. An early-morning 17-hydroxyprogesterone is the screening test; an ACTH stimulation test may follow a borderline result. Risk varies by ancestry and family history.
Ovarian hyperthecosis and tumors
Ovarian hyperthecosis involves nests of androgen-producing cells in the ovaries and is more common after menopause. Testosterone may be substantially elevated, with virilization and insulin resistance. Ovarian androgen-secreting tumors are rare but can progress quickly.
Adrenal tumors may produce DHEA-S, androstenedione, testosterone, or cortisol. Rapid symptoms, large biochemical elevations, abdominal fullness, or Cushing features increase concern.
Cushing syndrome and severe insulin resistance
Cortisol excess can cause hirsutism along with easy bruising, muscle weakness, wide purple stretch marks, facial rounding, high blood pressure, or diabetes. Severe insulin-resistance syndromes can produce marked acanthosis nigricans and ovarian androgen excess, sometimes with unusual fat distribution.
Medicines and menopause
Androgenic progestins, testosterone, DHEA, anabolic steroids, danazol, and valproate can contribute. After menopause, estrogen and SHBG decline, allowing a relative increase in androgen effect. Mild new facial hair can occur, but rapid or severe postmenopausal hirsutism should not be dismissed as aging.
Additional Tests and When Imaging Is Needed
The next tests depend on the panel, cycles, physical findings, and age. A fixed list is unnecessary for every patient.
Common additions include:
- 17-hydroxyprogesterone: screens for nonclassic congenital adrenal hyperplasia;
- pregnancy test: essential when periods are late or before certain treatments;
- TSH and prolactin: evaluate thyroid or pituitary causes of irregular periods;
- LH, FSH, and estradiol: help assess ovarian and pituitary function when amenorrhea is present;
- glucose testing and lipids: assess metabolic risk in PCOS;
- cortisol testing: used only when symptoms suggest Cushing syndrome;
- pelvic ultrasound: evaluates ovarian morphology or an ovarian mass when indicated;
- adrenal CT or MRI: used for a strongly adrenal biochemical pattern or rapid virilization.
An early-morning 17-hydroxyprogesterone test is particularly relevant when hirsutism begins early, the patient belongs to a higher-risk ancestry group, or A4 is elevated.
Imaging should generally follow biochemical confirmation. Ordering pelvic and adrenal scans for every case of mild gradual hirsutism creates incidental findings and does not improve diagnosis. Conversely, a markedly high confirmed testosterone, severe DHEA-S elevation, palpable mass, or rapid virilization should lead to prompt imaging even if PCOS is also possible.
Ultrasound can support PCOS diagnosis but is not required when ovulatory dysfunction and clear hyperandrogenism already establish two criteria in an adult. Ultrasound criteria also differ in adolescents, where normal pubertal ovarian appearance can mimic PCOS.
If total testosterone is unexpectedly extreme but the patient has no virilization, the clinician should first consider assay interference, supplement use, gel contamination, and repeat LC-MS/MS testing. This prevents unnecessary surgery or imaging based on a false result.
Treatment, Hair Removal, and Red Flags
Treatment has two parts: managing the underlying disorder and reducing unwanted hair. Hormone treatment does not remove existing terminal hairs immediately. It slows new growth and makes hairs finer over months, while cosmetic methods address current hair.
Medical treatment
For women not seeking pregnancy, combined oral contraceptives are a common first-line option. They suppress ovarian androgen production and increase SHBG, lowering free testosterone. The choice considers blood-clot risk, migraine history, smoking, blood pressure, age, and other contraindications.
If improvement is inadequate after about six months, an antiandrogen such as spironolactone may be added. Effective contraception is important because antiandrogens can affect development of a male fetus. Potassium and kidney monitoring depend on dose, age, health conditions, and other medicines.
Finasteride is another specialist option but also requires reliable pregnancy prevention. Flutamide is generally avoided because of liver toxicity. Metformin may improve metabolic health and cycles in PCOS but is not usually the most effective stand-alone treatment for hirsutism.
When pregnancy is desired, treatment focuses on the cause and ovulation rather than combined contraception or teratogenic antiandrogens. Referral to reproductive endocrinology may be appropriate.
Direct hair treatment
Shaving does not make hair grow back thicker; the blunt cut edge only feels coarser. Waxing, threading, plucking, depilatory creams, and bleaching are temporary options. Laser and intense pulsed light work best on pigmented hair and require attention to skin tone, device type, and operator experience. Electrolysis can treat light-colored hair and offers longer-term reduction but is slow.
Topical eflornithine can slow facial hair growth and may improve results when combined with laser. It does not remove existing hair and must be used continuously. Treating acne, ingrown hairs, and skin irritation can improve comfort while endocrine therapy takes effect.
Measuring response
Hair follicles cycle slowly. A meaningful medical response often takes six months, and maximum improvement may require nine to twelve months. Standardized photographs, shaving frequency, or a consistent score are more useful than daily checking. Treatment usually needs to continue because the underlying tendency persists.
Red flags
Prompt endocrine evaluation is needed for:
- hirsutism that becomes obvious over a few months;
- deepening voice or clitoral enlargement;
- rapid scalp recession or marked muscle change;
- total testosterone or DHEA-S several times the upper limit on a reliable repeat assay;
- a pelvic or abdominal mass;
- severe Cushing-like features;
- new substantial hirsutism after menopause.
Severe headache with vision change, acute pelvic pain, or symptoms of an adrenal crisis require urgent medical care. Most gradual hirsutism is not an emergency, but dismissing rapid virilization as PCOS can delay diagnosis of a serious disorder.
Documenting severity across different hair patterns
The modified Ferriman-Gallwey score can make follow-up more consistent, but it has limitations. Background hair growth differs with ancestry, age, hair color, and local grooming practices, and the score does not capture every androgen-sensitive area. A low score can still represent a major change for an individual, while frequent removal may hide the untreated pattern during an examination. The clinician should ask when growth began, how often hair is removed, and whether shaving or laser occurred before the visit.
Photographs taken with consent, a record of removal frequency, and the presence of acne, scalp thinning, cycle change, or virilization often provide a better baseline than a single score. Emotional burden also matters; treatment can be reasonable for patient-important hair growth even when laboratory results are normal and the numerical score is modest. The purpose of measurement is to track change and guide care, not to decide whether the concern is legitimate.
A treatment baseline should be recorded before starting hormonal therapy whenever possible. Combined contraception and antiandrogens can change testosterone, SHBG, and hair-growth rate, making later diagnostic testing harder to interpret. When treatment must begin promptly, documenting the original cycle pattern, photographs, medication list, and available laboratory results preserves useful context. Follow-up should then focus on slower new growth, less frequent removal, adverse effects, and reproductive plans rather than expecting every androgen concentration to normalize.
References
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women 2025 (Guideline)
- Approach to the Patient: Hirsutism 2025 (Review)
- Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines 2024 (Systematic Review)
- Practise Updates: Diagnosis and Management of Idiopathic Hirsutism 2024 (Review)
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023 (Guideline)
- Approach to androgen excess in women: Clinical and biochemical insights 2022 (Review)
Disclaimer
This article provides general education and does not replace examination, laboratory confirmation, or individualized treatment. Androgen results must be interpreted with assay method, age, symptoms, menstrual history, medications, and the speed of progression. Rapid virilization or markedly elevated confirmed androgens requires prompt specialist evaluation.
